Scrip 100
The latest Scrip 100 data set is now available and includes data on R&D spending, total revenues, employee numbers and sales for the top 100 biopharmaceutical companies (based on FY 2023).
• By
Pfizer continued its reign as the Scrip 100 leader for a third year, while Lilly and Novo climbed higher.
• By
Despite experiencing significant drops in pharmaceutical revenues in 2023, Pfizer and AbbVie maintained their top positions, ranking first and second respectively, in the latest Scrip 100.